Alnylam Pharmaceuticals (ALNY)
(Delayed Data from NSDQ)
$260.51 USD
-0.51 (-0.20%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $260.51 0.00 (0.00%) 5:26 PM ET
3-Hold of 5 3
F Value B Growth B Momentum C VGM
Brokerage Reports
Alnylam Pharmaceuticals, Inc. [ALNY]
Reports for Purchase
Showing records 401 - 417 ( 417 total )
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
R&R?s Week in Review: Oncology and Stem Cell Sectors
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
R&R?s Week in Review: Oncology and Stem Cell Sectors
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Another day, another brick on Alnylam''s IP wall; early, broad, fundamental RNAi patent allowed
Provider: RODMAN & RENSHAW, CO.
Analyst: SIMEONIDIS S
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Alnylam continues to extend its dominance in RNAi IP: additional Tuschl II patent granted
Provider: RODMAN & RENSHAW, CO.
Analyst: SIMEONIDIS S
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Nature Biotechnology paper offers further validation for Regulus'' microRNA platform
Provider: RODMAN & RENSHAW, CO.
Analyst: SIMEONIDIS S
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Alnylam continues to execute and capitalize on its partnerships; gets $20M from Takeda
Provider: RODMAN & RENSHAW, CO.
Analyst: SIMEONIDIS S